New combo aims to fight lung cancer without chemo
NCT ID NCT04013542
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests whether combining two immunotherapy drugs (ipilimumab and nivolumab) with radiation therapy is safe and effective for patients with stage II or III non-small cell lung cancer that cannot be surgically removed. The study enrolls 21 participants who have not received prior treatment for their current cancer. The main goal is to check for side effects, while also measuring how well the tumors respond.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Ipilimumab and nivolumab (immunotherapy drugs) plus radiation therapy
- What this could lead to
- If it works, this could point toward a new treatment option for locally advanced lung cancer that avoids chemotherapy.
- What could go wrong
- This is a very early (Phase 1) pilot trial with only 21 participants, so results may not apply broadly. Immunotherapy can cause serious immune-related side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALK GENE REARRANGEMENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Drug combo outsmart resistant lung cancer?
- Seeing Cancer's hidden markers: a new PET tracer could reveal who responds to targeted therapy
- Facing the fear: a new program aims to ease anxiety in advanced cancer
- Radiation hotspots may boost lung cancer treatment — a trial puts it to the test
- Lab-Grown lung tumors could reveal why some drugs work and others fail
- Could a simple assessment help older lung cancer patients tolerate chemo better?